Hims & Hers Health (NYSE:HIMS) Reaches New 1-Year Low After Analyst Downgrade

Hims & Hers Health, Inc. (NYSE:HIMS) hit a new 52-week low on Wednesday after Citigroup lowered their price target on the stock from $16.50 to $13.25. Citigroup currently has a sell rating on the stock. Hims & Hers Health traded as low as $13.74 and last traded at $15.4340, with a volume of 63819824 shares changing hands. The stock had previously closed at $15.51.

Several other research firms have also commented on HIMS. TD Cowen decreased their price target on shares of Hims & Hers Health from $20.00 to $17.00 and set a “hold” rating for the company in a research report on Tuesday. Wall Street Zen cut shares of Hims & Hers Health from a “hold” rating to a “sell” rating in a research report on Saturday, November 8th. Barclays initiated coverage on shares of Hims & Hers Health in a report on Monday, December 8th. They issued an “overweight” rating and a $48.00 price target on the stock. Morgan Stanley set a $21.00 price objective on Hims & Hers Health in a report on Tuesday. Finally, UBS Group set a $32.00 price objective on Hims & Hers Health in a research report on Tuesday, November 4th. Two equities research analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and four have issued a Sell rating to the stock. According to MarketBeat, Hims & Hers Health has a consensus rating of “Reduce” and an average target price of $32.27.

Insider Buying and Selling

In other Hims & Hers Health news, COO Michael Chi sold 13,750 shares of Hims & Hers Health stock in a transaction dated Wednesday, December 17th. The stock was sold at an average price of $36.71, for a total transaction of $504,762.50. Following the completion of the sale, the chief operating officer owned 305,161 shares of the company’s stock, valued at approximately $11,202,460.31. The trade was a 4.31% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Irene Becklund sold 8,411 shares of the stock in a transaction dated Wednesday, December 17th. The shares were sold at an average price of $36.71, for a total value of $308,767.81. Following the completion of the transaction, the insider directly owned 2,126 shares in the company, valued at $78,045.46. This represents a 79.82% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 82,963 shares of company stock worth $2,944,621 over the last three months. Corporate insiders own 17.71% of the company’s stock.

Key Hims & Hers Health News

Here are the key news stories impacting Hims & Hers Health this week:

• Positive Sentiment: Beat on EPS and subscriber growth — HIMS reported Q4 revenue up ~28% YoY and an EPS beat while saying subscribers have crossed 2.5 million, showing demand resilience. Hims & Hers Health Reports Mixed Q4 Earnings, Subscribers Cross 2.5 Million
• Positive Sentiment: Acquisition and 2026 revenue guidance provide upside potential — Management projects 2026 revenue of $2.7–$2.9B (above some estimates) and highlighted the Eucalyptus acquisition as an incremental revenue driver. Hims & Hers forecasts 2026 revenue above estimates
• Positive Sentiment: Bullish analyst/features note long‑term growth path — Bullish writeups highlight multi‑year international expansion, Eucalyptus’ contribution and a path to much larger revenue/EBITDA over time. Hims & Hers Health: Don’t Get Lost In The Weeds
• Neutral Sentiment: Unusual options activity — Heavy call buying was reported, which can indicate speculative bullish interest but is not definitive on fundamentals.
• Negative Sentiment: Soft near‑term guidance and margin pressure — Q1 revenue guidance came in below street estimates and margins showed contraction, prompting investor concern about short‑term growth and profitability. Hims & Hers Stock Slips Despite Q4 Earnings Beat, Margins Contract
• Negative Sentiment: Regulatory and SEC scrutiny — The company disclosed an SEC probe and management addressed scrutiny over compounding of GLP‑1 products, raising legal and operational risk for its core weight‑loss business. Hims & Hers Health discloses SEC investigation over copycat GLP-1s; stock falls
• Negative Sentiment: Analyst downgrades and price‑target cuts — Several firms trimmed forecasts and ratings (Citigroup cut its target to $13.25 with a sell), increasing near‑term sell pressure. Analyst price target and rating actions

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of the stock. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its stake in shares of Hims & Hers Health by 23.1% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 418,699 shares of the company’s stock worth $12,373,000 after purchasing an additional 78,543 shares during the period. Geneos Wealth Management Inc. acquired a new stake in Hims & Hers Health during the first quarter valued at $30,000. D.A. Davidson & CO. purchased a new position in Hims & Hers Health in the second quarter valued at $788,000. Ethic Inc. purchased a new position in Hims & Hers Health in the second quarter valued at $348,000. Finally, AlphaQuest LLC raised its position in shares of Hims & Hers Health by 110.2% in the second quarter. AlphaQuest LLC now owns 7,288 shares of the company’s stock worth $363,000 after acquiring an additional 3,821 shares during the period. 63.52% of the stock is owned by institutional investors and hedge funds.

Hims & Hers Health Stock Performance

The company has a debt-to-equity ratio of 1.67, a quick ratio of 1.64 and a current ratio of 1.88. The firm has a market capitalization of $3.51 billion, a PE ratio of 30.26, a price-to-earnings-growth ratio of 2.90 and a beta of 2.43. The firm’s 50 day moving average price is $27.79 and its 200-day moving average price is $39.76.

Hims & Hers Health (NYSE:HIMS) last announced its quarterly earnings results on Monday, February 23rd. The company reported $0.08 earnings per share for the quarter, beating the consensus estimate of $0.02 by $0.06. The firm had revenue of $617.82 million during the quarter, compared to analyst estimates of $619.48 million. Hims & Hers Health had a return on equity of 22.25% and a net margin of 5.47%.Hims & Hers Health’s revenue for the quarter was up 28.4% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.11 EPS. On average, research analysts expect that Hims & Hers Health, Inc. will post 0.29 EPS for the current year.

Hims & Hers Health announced that its Board of Directors has approved a stock repurchase program on Monday, November 17th that authorizes the company to repurchase $250.00 million in shares. This repurchase authorization authorizes the company to buy up to 3% of its shares through open market purchases. Shares repurchase programs are often an indication that the company’s board believes its shares are undervalued.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.